TC BioPharm plc is a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications. TC BioPharm plc is based in EDINBURGH, Scotland.
| Revenue (Most Recent Fiscal Year) | $4.76M |
| Net Income (Most Recent Fiscal Year) | $-15.53M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.03 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | 1.39 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.39 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.39 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $9.37 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | $-153.35 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 0.41M |
| Free Float | 0.35M |
| Market Capitalization | $0.12M |
| Average Volume (Last 20 Days) | 6162.45 |
| Beta (Past 60 Months) | 0.33 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 15.44% |
| Percentage Held By Institutions (Latest 13F Reports) | 16.25% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |